10 completed, 1 withdrawn. 11 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 10, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Cytomegalovirus Infection: new trials by email Literature Review of Cytomegalovirus Infection trials Research Report on Cytomegalovirus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 1 | Completed | ModernaTX, Inc. | 9 | 2021-11-08 | 2023-09-11 |
| Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults mRNA-1647, mRNA-1443, Placebo - Cytomegalovirus Infection | Phase 1 | Completed | ModernaTX, Inc. | 181 | 2017-11-13 | 2021-01-15 |
| Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation virus-specific T-Cells - Cytomegalovirus Infection, Adenovirus Infection | Phase 1 / Phase 2 | Withdrawn | St. Anna Kinderkrebsforschung | 2016-08-03 | 2019-05-09 | |
| Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV Low dose HB-101, Medium dose HB-101, High dose HB-101 - Cytomegalovirus Infection | Phase 1 | Completed | Hookipa Biotech GmbH | 54 | 2016-06-01 | 2018-04-03 |
| Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers MBX400, Placebo - Cytomegalovirus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2015-11-10 | 2017-12-26 |
| Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus multi-CMV epitope modified vaccinia Ankara vaccine, laboratory biomarker analysis - Cytomegalovirus Infection, Healthy, no Evidence of Disease | Phase 1 | Completed | City of Hope Medical Center | 24 | 2014-01-05 | 2017-08-02 |
| An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients ASP0113, Placebo - Dialysis, Healthy Subjects | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 48 | 2013-12-30 | 2024-10-17 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus CMV/AdV specific T cells - Cytomegalovirus Infection, Adenovirus Infection | Phase 1 | Completed | Baylor College of Medicine | 9 | 2009-05-01 | 2014-10-15 |
| Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge VCL CT02 pDNA vaccine, Towne CMV vaccine - Cytomegalovirus Infection | Phase 1 | Completed | University of California, San Francisco | 16 | 2006-10-01 | 2008-05-08 |
| Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Towne CMV vaccine - Cytomegalovirus Infection | Phase 1 | Completed | University of California, San Francisco | 10 | 2006-09-01 | 2007-01-11 |
Cytomegalovirus Infections (11) · Adenoviridae Infections (2) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Prolymphocytic (1) · Leukemia, Promyelocytic, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1)
DNA Virus Infections (11) · Herpesviridae Infections (11) · Infections (11) · Virus Diseases (10) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Neoplasms (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1) · Hematologic Diseases (1)
mRNA-1647 cytomegalovirus vaccine (2)
City of Hope Medical Center (2) · ModernaTX, Inc. (2) · University of California, San Francisco (2) · Astellas Pharma Global Development, Inc. (1) · Baylor College of Medicine (1) · Hookipa Biotech GmbH (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · St. Anna Kinderkrebsforschung (1)
United States (8) · Austria (1) · Belgium (1)
Mark A Jacobson, MD (2) · Caridad A. Martinez, MD (1) · Geert Leroux-Roels, MD PhD Prof (1) · John Zaia (1) · Ryotaro Nakamura (1) · Susanne Matthes, MD (1)
PMID 26853648, PMID 30562587, PMID 31285228, PMID 38324766, PMID 38478705, PMID 38526054
R01CA077544 (1)